- Home
- NCZ vs IPSC Comparison
NCZ vs IPSC Comparison
Compare NCZ & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | IPSC |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.7M | 248.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCZ | IPSC |
|---|---|---|
| Price | $14.43 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 57.9K | ★ 951.9K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $12.95 | $0.44 |
| 52 Week High | $16.17 | $2.97 |
Technical Indicators
Market Signals| Indicator | NCZ | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 45.75 |
| Support Level | $14.22 | $1.22 |
| Resistance Level | $14.60 | $2.45 |
| Average True Range (ATR) | 0.31 | 0.14 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 77.76 | 42.05 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of current income, current gains and long-term capital appreciation. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.